Strategies for Community Adoption of Bispecifics into Treatment of Relapsed/ Refractory Multiple Myeloma

Video content above is prompted by the following:

• Which strategies have you found effective in encouraging the adoption of bispecifics in R/R MM treatment?
• Discuss any educational initiatives or protocols that have been successful
• Address common concerns or any hesitations from colleagues.
• How can we improve the transition of care for patients receiving bispecifics between academic centers and community practices?
• Explore any challenges in this transition.
• Share best practices for communication and coordination between settings.
• In your experience, what are the key factors influencing community oncologists' adoption of bispecifics in R/R MM, and how can academic centers support this process?
• Address any misconceptions about bispecifics usage in community settings.
• Identify necessary resources or support systems to increase comfort levels in prescribing and managing bispecifics.
• Explore potential partnerships, training programs, or consultative services between academic and community practices.
• What are some data updates at IMS that you are excited about regarding bispecifics in R/R MM?
• Before we close, I would like each of you to share some key takeaways and clinical pearls on the use of bispecifics for patients with R/R MM for your community colleagues.
• Please share your closing thoughts